Background: Genetic screens in Drosophila melanogaster and Caenorhabditis elegans identified the kinase suppressor of Ras, Ksr, as a new component in the Ras intracellular signaling pathway. In these organisms, mutations in Ksr resulted in attenuation of Ras-mediated signaling. Homologs of Ksr have also been isolated from mice and humans; their precise role in Ras signaling is not well defined. Here, we present data showing interactions between the murine form of Ksr (mKsr-1) and other components of the Ras pathway.
Background
The Ras family of small membrane-bound GTPases is an integral part of many regulated signal transduction pathways that transmit proliferative and differentiative signals [1, 2] . Regulation of the GTPase activity of Ras is crucial, because only the GTP-bound form of Ras is active. One welldefined pathway by which Ras-mediated signals are transduced from the plasma membrane to the nucleus includes the sequential activation of the serine/threonine kinase Raf, the dual-specificity kinase MEK (also called mitogen-activated protein (MAP) kinase kinase; MAPKK) and MAP kinase (also called extracellular signal-regulated kinase; ERK) [3] . Amplification of ras proto-oncogenes and mutations that constitutively activate Ras protein are frequent in many types of human cancer [4] , making components of this pathway attractive therapeutic targets [5] . Recently, genetic studies of Ras signaling in Drosophila melanogaster and Caenorhabditis elegans revealed the existence of a novel component, Ksr (kinase suppressor of Ras), which is required for signaling by activated Ras [6] [7] [8] . Studies in flies and worms, and the isolation of mammalian Ksr homologs, suggested that Ksr belongs to a new family of proteins [6] . Protein sequence comparison shows that the protein most closely related in sequence to Ksr is Raf, by two criteria: first, the presence of a cysteine-rich domain within the amino-terminal region, and second, a putative kinase domain in the carboxy-terminal region of Ksr that has the most similarity to that of Raf [6] [7] [8] [9] . Studies of v-Ras signaling showed that Ksr participates in regulating the MAP kinase pathway [10] . The goal of the present study was to determine the role of the murine form of Ksr (mKsr-1) in signaling by cellular Ras (c-Ras), and in so doing, to investigate where in the MAP kinase pathway Ksr may operate.
Results

Association of mKsr-1 with MEK-1 and ERK-2
To investigate where in the MAP kinase pathway Ksr may operate, a yeast two-hybrid screen [11, 12] was used to identify molecules that interact with mKsr-1. The fulllength mKsr-1 protein contains five conserved regions, CA1-CA5. The amino-terminal region (CA1-CA4, amino acids 1-564) or the carboxy-terminal region (CA5, the putative kinase domain, amino acids 541-873) [6] of mKsr-1 was fused to the LexA DNA-binding domain [13] . These fusion constructs were screened against a library of HeLa cell cDNAs that had each been fused to the DNA sequence encoding the Gal4 transcriptional activation domain. The carboxy-terminal region (CA5) of mKsr-1 interacted with three cDNA clones that contained human MEK-1 sequences (Figure 1a ) [14] , whereas the amino-terminal region (CA1-CA4) failed to interact with MEK-1. CA5 did not interact directly with c-Raf-1 (Figure 1a ), even though a positive interaction was observed between Raf and Ras (data not shown) in the same experiment. It is possible that the co-immunoprecipitation of Raf and Ksr reported previously [10, 15] was due to an indirect interaction mediated by MEK, or a member of the 14-3-3 protein family [15] . The results described above indicate that there is a specific interaction between MEK-1 and the carboxyterminal region of mKsr-1 in a yeast two-hybrid assay.
To determine whether the association of MEK-1 and mKsr-1 can occur in mammalian cells, COS-7 cells were co-transfected with plasmids encoding mKsr-1 tagged with the Glu-Glu epitope and plasmids encoding either mouse MEK-1 tagged with the influenza hemagglutinin (HA) epitope or MKK-4 tagged with the FLAG epitope. In co-immunoprecipitation experiments, mKsr-1 was found in immunoprecipitates of HA-MEK-1 ( Figure 1b Figure 1c, lanes 1,2) . In agreement with the results seen in yeast, the carboxy-terminal region of mKsr-1 (CA4-CA5), but not the amino-terminal region (CA1-CA4), was responsible for the interaction with MEK-1 in mammalian cells (Figure 1c, lanes 3-8) . In fact, CA5 itself was sufficient for the interaction with MEK-1 (data not shown). Despite the association between mKsr-1 and MEK-1, MEK-1 does not appear to be a substrate for mKsr-1 in vitro (data not shown). Serum treatment of cells did not significantly alter the mKsr-1-MEK-1 interaction (Figure 1c , compare lanes 1 and 2). In addition, tumor necrosis factor α (TNFα), recently reported to regulate the activity of mKsr-1 [16] , did not affect the formation of the mKsr-1-MEK-1 complex (data not shown).
In contrast to the strong association between mKsr-1 and MEK-1, we reproducibly detected a weaker interaction between mKsr-1 and MAP kinase, or murine ERK-2. This was assayed by both two-hybrid interactions in yeast and co-immunoprecipitation in COS-7 cells (Figure 1d ). The interaction was mediated specifically by the amino-terminal region of mKsr-1 (Figure 1d ).
Overexpression of mKsr-1 in COS-7 cells inhibits signaling of the MAP kinase pathway
To explore the biological consequences of the interaction between MEK-1 and mKsr-1, we tested whether mKsr-1 might modulate the phosphorylation and/or activity of MAP kinase. After co-transfection of mKsr-1 and HA-ERK-2 into COS-7 cells, HA-ERK-2 activity was measured in vitro using myelin basic protein (MBP) as the substrate. Control cells transfected with vector plus HA-ERK-2, showed a strong induction of MAP kinase activity upon serum treatment (Figure 2a ). When cells were co-transfected with the same amount of HA-ERK-2 and increasing amounts of full-length mKsr-1, the ability of serum to stimulate MAP kinase activity was significantly impaired in a manner dependent upon the dose of mKsr-1 (Figure 2a,b) . The inhibitory property of mKsr-1 was localized within its carboxy-terminal region, which contains the putative kinase domain, CA5 (Figure 2c ). This is in agreement with previous data [10] . As a control, expression of the amino-terminal portion of mKsr-1 (CA1-CA4) did not have an inhibitory effect on serum-induced MAP kinase activation. Analyses using an antibody that specifically recognizes phosphorylated ERK revealed that concomitant with the inhibition of ERK activity, phosphorylation of ERK was also blocked (data not shown). The action of mKsr-1 appears to be specific for the MAP kinase cascade, given that mKsr-1 failed to block c-Jun N-terminal kinase (JNK) activation by both serum and TNF receptor-associated factor 2 (TRAF2; data not shown) [17] [18] [19] .
The ability of mKsr-1 to inhibit MAP kinase correlates with its capacity to bind MEK To address whether the mKsr-1-MEK-1 interaction is important for the ability of mKsr-1 to inhibit serum-stimulation of MAP kinase, point mutations were introduced within CA5 of mKsr-1, to disrupt this interaction. In the case of c-Raf-1, the interaction of c-Raf-1 with MEK-1 is markedly reduced when Lys375 in the ATP-binding site [20] is mutated to methionine [21] . By analogy to c-Raf-1, the same outcome was seen when Arg589 of mKsr-1, the equivalent amino acid in its putative ATP-binding site, was changed to leucine (R589L; Figure 3a , lanes 1-5). Moreover, mKsr-1R589L did not inhibit induction of MAP kinase activity, when co-expressed with HA-ERK-2 ( Figure 3b , upper panel). This suggests that the inhibitory effect of wild-type mKsr-1 on MAP kinase activation may be due to its association with MEK-1. Another mutant tested was the murine counterpart to a recessive-lethal Ksr mutant isolated in D. melanogaster [6] . The mutant mKsr-1G580V/A587T displayed a decreased association with MEK-1 ( Figure 3a , lanes 6-7), but nevertheless inhibited MAP kinase activation. The inhibition occurred to a lesser extent than with wild-type mKsr-1 ( Figure 3b , upper panel). In view of its inhibitory effect, mKsr-1G580V/A587T might affect other molecules important for MAP kinase activation. The data presented here establish that the mKsr-1-MEK-1 interaction is clearly involved.
It is well documented that, when activated, c-Raf-1 associates with, directly phosphorylates, and stimulates, MEK-1 [22] [23] [24] . Perhaps mKsr-1 inhibits MAP kinase activation by serum because it competes with c-Raf-1 for MEK-1. We were unable to detect a decrease in the amount of MEK-1 associated with mKsr-1 upon serum stimulation, possibly because only about 3% of Raf is activated by serum [25] . When mKsr-1 was co-expressed with v-Ras or c-Raf-1, less MEK-1 was found to be associated with mKsr-1 than when mKsr-1 was co-expressed with the control vector alone (Figure 3c , compare lanes 2 and 3 with lane 1). These data suggest a competition for a common pool of MEK-1 amongst mKsr-1, v-Ras and c-Raf-1. Indeed, of all the known kinase sequences in the database, the kinase domain of mKsr-1 is most homologous to that of c-Raf-1 (60% amino-acid sequence similarity) [6] [7] [8] [9] [10] . Consistent with this notion, overexpression of mKsr-1 in COS-7 cells also inhibited MAP kinase activation mediated by v-Ras and v-Raf, but not the activation mediated by MEK-1 ( Figure 3d ).
Microinjection of mKsr-1 blocks DNA synthesis in rat embryo fibroblasts
The activation of the MAP kinase cascade is known to be sufficient for G1-to S-phase progression in the cell cycle [26] [27] [28] [29] . To test the role of mKsr-1 in this progression, mKsr-1 constructs were microinjected into rat embryo fibroblasts (REF52) and S-phase entry was assessed by visualization of 5-bromodeoxyuridine (BrdU) incorporation into newly synthesized DNA. When fulllength mKsr-1 cDNA (Figure 4a ) was microinjected into nuclei and the cells subsequently stimulated with serum, BrdU was incorporated into 2.5% of the cells (Figure 4g ), Effect of mKsr-1 overexpression on MAP kinase activity. COS-7 cells co-transfected with different Glu-Glu-tagged mKsr-1 constructs and HA-ERK-2 were treated with 10% calf serum or left untreated. HA-ERK-2 was immunoprecipitated from one third of each cell lysate and subjected to a kinase activity assay using MBP as the substrate. Interaction between murine ERK-2 (mERK-2)and the amino-terminal region of mKsr-1. Plasmids encoding the amino-terminal (CA1-CA4), or carboxy-terminal (CA5) region of mKsr-1 fused with LexA DNAbinding domain were co-transformed with plasmids encoding fulllength mERK-2 fused with the VP16 transcription activation domain, into the yeast strain L40 [13] . Three colonies from each transformation were filter-assayed for β-galactosidase activity (upper panel). For the lower panel, COS-7 cells were co-transfected with HA-mERK-2 and Glu-Glu-mKsr-1 constructs: full length (FL), CA1-CA3 or CA4-CA5. Cell lysates were immunoprecipitated (IP) with either anti-HA antibody or anti-Glu-Glu antibody and blotted with the specified antibodies. Glu-Glu-tagged TRAF2 was used as a negative control. Positions of the immunoprecipitated molecules are indicated. (Figure 4g ). Since lysine is the critical ATP-binding residue for all other known kinases, R589 in mKsr-1 was mutated to lysine. Injection of mKsr-1R589K inhibited DNA synthesis to the same extent as wild-type mKsr-1 (data not shown). Thus, it appears that inhibition of DNA synthesis by mKsr-1 requires its kinase activity. The mechanism of this inhibition is not understood. In addition, when the Ksr mutant mKsr-1G580V/A587T, equivalent to the D. melanogaster Ksr mutant that blocks v-Ras signaling [6] , was microinjected into REF52 cells, BrdU incorporation was partially inhibited (40%; Figure 4g ), consistent with the results obtained from COS-7 cells (Figure 2c ). Strikingly, the inhibitory effect of full-length mKsr-1 on BrdU incorporation was fully overcome by co-injecting mKsr-1 with HA-MEK-1 (Figure 4f ; 77% BrdU incorporation in Figure 4g ), but not by co-injection of mKsr-1 and FLAG-MKK-4 ( Figure 4e ). The same results were obtained when NIH fibroblasts were microinjected with the cDNAs described above (data not shown). In all, results from REF52 and COS-7 cells suggest that, under these conditions, mKsr-1 is capable of sequestering MEK-1 so that it is not available for the activation of MAP kinase, and this, in turn, plays a role in preventing cells from entering S phase.
Discussion
Our studies have demonstrated that mKsr-1 participates in the MAP kinase pathway by directly interacting with two Inhibition of DNA synthesis by mKsr-1. (a-f) Images of immunofluorescent staining. All the left panels (a,c,e) show the staining of mKsr-1 proteins using anti-Glu-Glu antibody and Cy3 secondary antibody (red). All the right panels (b,d,f) show the staining of newly synthesized DNA in the cell nucleus visualized by antiBrdU antibody and FITC-conjugated secondary antibody (green), using methods as described [14] . Arrows indicate one example of the same microinjected cell stained for mKsr-1 protein expression (red) and DNA synthesis (green). (g) Graph of the proportion of cells that were BrdU-positive out of the total number of microinjected cells. components of the pathway, MEK and ERK. In contrast to a recent report [16] , we have been unable to show any phosphorylation or activation of Raf by mKsr-1 (data not shown).
Although we have not assigned a definite function to mKsr-1, here we report, for the first time, an interaction of mKsr-1 with MEK and ERK. Given that the mKsr-1-MEK-1 complex pre-exists without growth-factor stimulation, we propose that mKsr-1 may serve as a scaffold protein for the docking of MEK and its substrate ERK (Figure 5a ). In contrast to the MEK-Ksr interaction, the interaction between Ksr and ERK may be transient, because ERK is known to enter the nucleus upon its phosphorylation and activation by MEK [30] [31] [32] [33] [34] [35] . Other proteins with a scaffold function in kinase pathways include Ste5 [36] , Pbs2 [37] , A-kinase anchoring protein 79 (AKAP79) [38] and Gravin [39] . As a scaffold protein, mKsr-1 might help prevent crosstalk between multiple MAP kinase modules or prevent different stimuli from leading to the activation of one particular module, especially because there are known to be several activators for MEK-1 [40] [41] [42] [43] [44] [45] . Moreover, Ksr mutants were isolated in genetic screens on the basis of their ability to abrogate signaling by activated Ras, implicating Ksr as a positive regulator [6] [7] [8] [9] [10] , whereas the inhibition of MAP kinase activation by overexpression of mKsr-1 in mammalian cells suggests that mKsr-1 is a negative regulator. The 'scaffold model' offers a possible resolution to this paradox (Figure 5a ). In the genetic screens, Ksr mutants that inhibit signaling by activated Ras may do so because they have a weakened interaction with MEK. In the overexpression system in mammalian cells, mKsr-1 effectively sequesters MEK-1, most likely away from c-Raf-1, to form non-productive signaling complexes, thereby preventing MAP kinase from being activated.
Another possibility is that the experimental system employed here may not fully reflect the genetic systems. For instance, maybe additional stimuli activate Ksr in cells within the organisms used in genetic screens and are not present or strong enough in serum-stimulated cells in culture (Figure 5b ). Until such putative stimuli are found, it will be difficult to address this possibility. Alternatively, the physiological role of mKsr-1 may be to 'fine tune' the availability of MEK to the MAP kinase cascade or to inhibit MAP kinase signaling by inhibiting MEK activity. The inhibitor hypothesis is less likely, because co-expression of mKsr-1 with constitutively active MEK-1 [46] had no effect on MEK activity (data not shown). This hypothesis is in conflict with the genetic data as well. In view of the apparent positive regulatory role of mKsr-1 predicted from the genetic studies, we favor the scaffold hypothesis, which accounts for the genetic results as well as for our findings that mammalian Ksr binds directly to MEK and ERK and inhibits the MAP kinase pathway when overexpressed. In our studies of Ksr mutants, there was a correlation between the function of these mutants in both the Drosophila genetic system and the cell-based system with their ability to interact with MEK. This also favors the scaffold model. The recognition that mKsr-1 and MEK-1 directly interact should facilitate further work on the role of mammalian Ksr in signal transduction pathways that lead to growth and differentiation.
Materials and methods
Plasmids, antibodies, tissue culture and transfection
Murine Ksr-1 cDNA sequences tagged with the Glu-Glu epitope (EYMPME in single-letter amino-acid code) were cloned into the pcDNA3 expression vector from Invitrogen. HA-tagged ERK-2 and FLAG-tagged MKK-4 were cloned into the pCG expression vector. Antibodies against Glu-Glu, HA and FLAG epitopes were generated ourselves, or purchased from Boehringer Mannheim or Kodak, respectively. Rabbit polyclonal antibodies were generated against mKsr-1 peptide sequences DALLEMDEAKAKEMLRR and EEPEAGKSEAED-DEEDEVDD by Chiron Mimotopes. COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum (CS) and L-glutamine. Cells were transiently transfected by the TransIT-LT-1 transfection reagent (Pan Vera) according to manufacturer's instructions. buffer) for 16 h. Cells were then either left untreated or stimulated with 10% CS for 5 min. Cells were lysed in buffer of the following composition: 50 mM Tris pH 7.4, 133 mM NaCl, 1% NP-40, 10% glycerol, 1 mM Na 3 VO 4 , 50 mM NaF, 50 mM NaPPi, 1 mM benzamidine, 1mM phenylethylsulfonyl fluoride, 10 mg/ml leupeptin and 10 mg/ml aprotinin), and lysates were clarified by centrifugation. HA-tagged MEK-1 or Glu-Glu-tagged mKsr-1 were immunoprecipitated with anti-HA and anti-Glu-Glu antibodies, respectively. Immunocomplexes were collected by binding to protein-A-Sepharose, washed once in 50 mM Tris pH 7.5, 0.5 M LiCl, 0.5% NP-40, once in 50 mM Tris pH 7.5, 0.5 M LiCl and once in 10 mM Tris pH 7.5. After addition of Laemmli loading buffer, samples were subjected to SDS-PAGE. Western blot analysis was performed using either the alkaline phosphatase detection system or the enhanced chemiluminescence labeling system from Amersham.
Immunoprecipitation and western analysis
MAP kinase assay
The MAP kinase assay was performed at room temperature for 20 min in kinase buffer: 25 mM Tris pH 7.5, 10 mM MgCl 2 , 2 mM DTT, 0.1 mM Na 3 VO 4 , 50 µM ATP (adenosine triphosphate), 10 µCi of [γ 32 P]ATP and 0.2 mg/ml of substrate, MBP. Reaction products were subjected to SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was used for both autoradiography, to detect the phosphorylation state of the MBP substrate, and for western blot analysis to determine the expression level of ERK-2.
Yeast two-hybrid screen
Yeast host L40 strain, previously transformed with pCY4 encoding a LexA fusion with the carboxy-terminus of mKsr-1 (CA5), was transformed with the HeLa cell cDNA library constructed in the pGAD-GH vector (Stratagene). Over 120 million yeast transformants were plated onto medium containing 3 mM 3-aminotriazole, which is selective for transcriptional activation of the HIS3 gene [11] [12] [13] . Colonies grown for 6 days were then assayed for β-galactosidase activity by a filter assay. Library plasmids from clones positive for both HIS3 expression and β-galactosidase activity were retransformed into L40 along with pCY4, to eliminate false positives. To check for specificity of an interaction, control plasmids encoding a LexA fusion with a different signaling molecule or a Gal4 activation domain fusion with the amino-terminus of mKsr-1 were used. The full-length mKsr-1 was found to be unable to interact with MEK-1 clones, consistent with previous reports [6, 16] , possibly due to instability of full-length mKsr-1 protein or a structural hindrance for interaction in yeast.
Measurement of DNA synthesis
REF52 or NIH cells were plated on coverslips and grown in DMEM supplemented with 10% CS. After cells had been serum-starved for 30-36 h to render them quiescent, pcDNA3-Ksr-Glu-Glu expression constructs (5 µg/ml) were microinjected into the nuclei. Cells were treated with 15% fetal CS and BrdU for 16-18 h. Cells were fixed in methanol. Ksr expression was measured by immunofluorescence using an anti-Glu-Glu mouse monoclonal antibody and a Cy3-conjugated donkey anti-mouse secondary antibody. BrdU incorporation was visualized with a FITC-labeled anti-BrdU antibody (Boehringer Mannheim BrdU labeling and detection kit) as described [47] .
